how genetic variations and drug interactions may decrease the efficacy of clopidogrel (Plavix)
July 2009
New labeling will focus on how genetic variations and drug interactions may decrease the efficacy of clopidogrel (Plavix).
These factors can lead to less efficient CYP2C19 metabolism...one of the main enzymes that convert clopidogrel to its active form.
Genetics. About 30% of whites and blacks and over 50% of Asians have variations that decrease clopidogrel metabolism. This might translate to a higher risk for cardiac events.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote